Cognitive dysfunction is among the most disabling non-motor symptoms experienced by people with Parkinson’s disease. Although cognitive interventions may improve cognitive functioning, reported effects are generally small and heterogeneous. The review therefore examined prognostic factors and predictive models associated with responsiveness to cognitive interventions rather than focusing only on their average effects.

The researchers searched MEDLINE, the Web of Science Core Collection and CINAHL through June 2025. Eligible full-text publications were written in English, German or Italian and included adults with Parkinson’s disease, regardless of sex or cognitive status. Studies were required to investigate prognostic factors or predictive models for cognitive or non-cognitive outcomes.

Across the included publications, researchers used 11 approaches for identifying prognostic factors and one factor-finding model. Individual-related factors, including age, education and baseline cognitive performance, were investigated more frequently than intervention-related features such as analogue versus digital delivery. The clearest and most consistent association was between lower baseline cognitive performance and greater gains after cognitive intervention. This was an observed association, not evidence that a particular program will benefit every patient with the same baseline cognitive score.

The findings were synthesized narratively, and methodological quality was assessed with the Quality in Prognosis Studies tool. The risk-of-bias assessment revealed substantial limitations across the literature, while differences among the studies complicated direct comparison of candidate prognostic factors. The authors therefore concluded that determining which characteristics influence responsiveness to cognitive intervention in Parkinson’s disease remains an important research gap.

Subject of Research: Prognostic factors associated with responsiveness to cognitive interventions in adults with Parkinson’s disease

Article Title: Prognostic factors for cognitive intervention responsiveness in Parkinson's disease: a systematic review revealing inconsistent methodology and evidence

Article References: Colucci, A., Berri, M., Ophey, A., Fiorenzato, E., Kalbe, E., & Folkerts, A.-K. (2026). Prognostic factors for cognitive intervention responsiveness in Parkinson's disease: a systematic review revealing inconsistent methodology and evidence. Frontiers in Cognition, 5, Article 1959713. https://doi.org/10.3389/fcogn.2026.1959713

Image Credits: AI Generated

DOI: 10.3389/fcogn.2026.1959713

Keywords: Parkinson’s disease, cognitive intervention, baseline cognition, treatment responsiveness, prognostic factors, predictive models, systematic review, methodological quality, Prognostic, factors, cognitive, intervention

The stakes could hardly be higher. Neonatal respiratory disorders remain among the leading causes of illness and death in the first weeks of life, contributing significantly to the roughly 2.3 million neonatal deaths reported worldwide each year. Preterm infants are especially vulnerable because their lungs are structurally and functionally immature, leaving them exposed to respiratory distress syndrome, bronchopulmonary dysplasia, and prolonged dependence on ventilators. Even in wealthy countries with state-of-the-art intensive care, these conditions carry short- and long-term consequences, including chronic pulmonary disease and impaired neurodevelopment.

Traditional respiratory assessment in newborns relies on clinical examination, blood gas analysis, and conventional imaging — tools the review describes as fundamentally limited. Different clinicians can interpret the same chest X-ray or lung sounds differently, a problem known as interobserver variability. Conventional methods also have limited ability to predict how a baby’s condition will evolve, and they struggle to integrate the complex, constantly changing streams of data generated in an intensive care unit. In a setting where minutes can matter, those limitations become critical.

To map the emerging alternatives, the Brazilian team followed the PRISMA-ScR reporting guidelines and registered their protocol on the Open Science Framework. They searched PubMed/MEDLINE, Embase, Scopus, Web of Science, and IEEE Xplore for studies published between January 2015 and March 2026, combining controlled descriptors with free-text terms covering neonates, respiratory assessment, digital health, and artificial intelligence. From 199 initially identified records, independent reviewers whittled the pool down through duplicate removal, title and abstract screening, and full-text review, ultimately including 35 studies — just 18.5 percent of what they started with. Studies lacking a neonatal population, respiratory outcomes, or actual AI components were excluded, as were those with fewer than ten patients.

The technological landscape that emerged is dominated by machine learning. Twenty-one of the 35 studies — 60 percent — used machine-learning approaches, most commonly XGBoost, support vector machines, random forests, and ensemble models. Deep learning appeared in ten studies, or 28.6 percent, typically built on convolutional neural networks, ResNet architectures, BiLSTM networks, and U-Net for analyzing images and physiological signals. Three studies used hybrid machine learning and deep learning models, and one deployed an intelligent closed-loop control system. Electronic health records were the most common data source at 34.3 percent of studies, followed by physiological signals, chest radiography, digital auscultation, ventilator-derived data, and a scattering of other technologies including lung ultrasound, spectroscopy, and video imaging.

The review identified three major application domains. The largest was predictive modeling: algorithms trained largely on routinely collected clinical data to forecast outcomes such as bronchopulmonary dysplasia, respiratory distress syndrome, the need for mechanical ventilation, and extubation failure. Many of these models reported high predictive performance, and the authors suggest they are the closest to genuine clinical implementation. Yet the field is fragmented — datasets, outcome definitions, and methodologies vary so widely from study to study that comparing models head-to-head is nearly impossible, and most evidence comes from retrospective designs without robust external validation.

The second domain is medical imaging. Roughly a quarter to a third of the studies applied deep learning to chest radiographs and lung ultrasound, enabling automated classification of neonatal respiratory diseases. These tools showed particular promise for reducing interobserver variability and standardizing diagnosis — a meaningful advantage in hospitals with limited access to specialist radiologists. Some studies went further, assessing agreement between human readers and AI models interpreting lung ultrasound scans. But imaging-based AI carries its own dependencies: it requires standardized image acquisition, high-quality annotations, and multicenter validation to perform reliably across different populations and equipment, none of which is yet guaranteed.

The third domain, continuous physiological monitoring, may be the most futuristic. Researchers are developing noninvasive systems using sensors, video cameras, radar, wearable devices, and photoplethysmography to track oxygen saturation, respiratory rate, and ventilatory patterns in real time — some without touching the baby at all. Other creative approaches include separating heart and lung sounds from noisy recordings, detecting apnea from thermal video, analyzing newborn cry acoustics to distinguish sepsis from respiratory distress, and even using mid-infrared spectroscopy of gastric aspirates to predict the need for prolonged respiratory support. These systems demonstrated feasibility for early detection of clinical deterioration, but they are highly susceptible to motion artifacts, environmental interference, and variations in how a baby is positioned — and they remain at an early stage of clinical validation.

Perhaps the most significant trend the authors identified is the move toward multimodal AI, which fuses clinical, physiological, and imaging data into more comprehensive predictive models. Such integration could give clinicians a far richer picture of an infant’s respiratory trajectory than any single data stream. But it also raises the bar considerably, demanding data standardization, interoperability between hospital systems, and substantial technological infrastructure — resources that are unevenly distributed across healthcare settings worldwide.

The review’s bottom line is a sobering counterweight to the hype. Beyond methodological heterogeneity and small samples, the authors flag poorly explored questions of algorithmic bias, equity in model performance, and clinical safety, along with the low interpretability of many deep learning models — a serious barrier in environments requiring rapid, transparent decisions. Their prescription is clear: the field must move beyond proof-of-concept studies toward prospective, multicenter validation trials, standardized protocols, transparent model reporting, and careful integration into clinical workflows, with attention to ethical and regulatory dimensions. AI may eventually become an indispensable assistant in the neonatal unit, but for now, the babies’ breathing is still being judged by human ears, eyes, and hands.

Subject of Research: Artificial intelligence and digital technologies for neonatal respiratory assessment

Article Title: Artificial intelligence and digital technologies transforming neonatal respiratory assessment: a scoping review

Article References: Ribeiro, S. N. S., Vargas, M. E. R. R., Velame, R. D. C., Fernandes, A. E. R., Filho, M. A. T., Leão, R. N., Maia, H., Pereira, S. A., & Rodrigues-Machado, M. D. G. (2026). Artificial intelligence and digital technologies transforming neonatal respiratory assessment: a scoping review. Journal of Perinatology. https://doi.org/10.1038/s41372-026-02894-5

Image Credits: AI Generated

DOI: 10.1038/s41372-026-02894-5

Keywords: artificial intelligence, machine learning, deep learning, neonatology, respiratory assessment, bronchopulmonary dysplasia, lung ultrasound, chest radiography, continuous monitoring, neonatal intensive care, predictive models, scoping review

The scale of the challenge explains why no single institution is attempting it alone. Modern AI models in biology, from protein structure prediction to whole-cell simulators, are ultimately limited by the quality and breadth of the experimental data used to train them. Today’s datasets capture cell responses to interventions across only a small fraction of the cell types and conditions that matter in human health. The Virtual Biology Initiative is designed to close that gap by coordinating data generation across institutions and disciplines, expanding cell response measurements to far more cell types and conditions than have yet been studied, and building and validating technologies capable of studying cells and their interactions at greater scale, speed, and accuracy. The result, organizers say, will be a foundational, openly accessible dataset that no laboratory, company, or government agency could produce on its own.

The federal contribution anchors the effort on two fronts. The Department of Energy’s Office of Science will invest more than $500 million over five years in laboratory measurement, modeling, and computation toward building the AI-ready open data resource. That investment flows through the Genesis Mission, a cross-agency initiative led by DOE, and draws on some of the most powerful scientific infrastructure in the world: exascale supercomputing, X-ray and neutron scattering facilities, cryo-electron microscopy and tomography, and autonomous laboratories distributed across the National Laboratory system. Darío Gil, DOE’s Under Secretary for Science, framed the partnership as a new standard for open science, pointing to the combination of DOE’s computing and measurement assets — including user facilities at the Joint Genome Institute, the Environmental Molecular Sciences Laboratory, and advanced structural beamlines — with Biohub’s AI models, tool development, and biological data capabilities.

The National Institutes of Health, for its part, will coordinate the contribution of relevant datasets, repositories, and knowledge bases developed through more than $500 million in prior federal investment aligned to the initiative. Through its Bio Genesis Mission, NIH plans to bring together existing biomedical datasets, national data infrastructure, and research programs to help build AI-ready resources for the broader scientific community. The resources in play are substantial: national biomedical repositories catalogued by NIH’s National Library of Medicine and the National Center for Biotechnology Information, as well as NIH Common Fund programs that are already developing coordinated biological atlases, shared data standards, and AI-ready biomedical datasets. Biohub will work with NIH to standardize these datasets for AI model training, a step that many researchers consider as important as the raw data itself, since heterogeneous formats and inconsistent annotations have long hampered large-scale machine learning in biology.

Industry is contributing at significant scale as well. Google DeepMind, Isomorphic Labs, and Meta are collectively investing $300 million in the Virtual Biology Initiative to create the technologies and multi-modal datasets needed to build predictive models of life. Max Jaderberg, President of Isomorphic Labs, emphasized that generating the data required for predictive systems biology means scaling past the limits of what any single organization can produce today, and described the initiative as building a massive, multimodal data foundation intended to push the industry toward the next significant breakthrough in biology. Pushmeet Kohli, Vice President of AI for Science at Google DeepMind and Google Cloud’s Chief Scientist, argued that the quest to build a virtual cell is one of the great collective scientific challenges and cannot be solved without open, experimental biological data at an unprecedented scale showing how living cells behave and respond to change. In his view, the investment will help create an open, standardized data commons that lays the foundation researchers worldwide need to better model biology.

Biohub’s own founding commitment of $500 million anchors the scientific core of the program. Of that sum, $400 million supports new technologies that expand what biologists can measure. Among them is cryo-electron tomography, an imaging technique that resolves structures at near-atomic detail inside the cell, allowing researchers to observe molecular machines in their native cellular environment rather than in isolation. Another is advanced microscopy capable of imaging millions to billions of cells in living tissue, which would make it possible to capture how entire organs respond to perturbations at single-cell resolution. The remainder funds engineering tools to build and perturb biology at molecular, cellular, tissue, and whole-organism levels — the experimental manipulations that give AI models the cause-and-effect data they need to learn how biological systems respond to change. A further $100 million funds research outside Biohub, extending the reach of the program across the wider scientific community.

The initiative has also drawn in leading scientific institutions and consortia with experience organizing transformative international collaborations, from the Human Genome Project onward. The Allen Institute, Broad Institute, Gladstone Institutes, the Human Cell Atlas, the Human Protein Atlas, and the Wellcome Sanger Institute have come together to help nucleate the scientific community across academia and industry around developing effective strategies to maximize the impact of virtual biology. These groups are committed to working together as part of the Virtual Biology Initiative as well as through independent efforts toward the shared goal. NVIDIA will support the initiative by leveraging accelerated computing infrastructure, domain-specific software, and technical expertise, while Renaissance Philanthropy is helping to expand funding for data generation. The breadth of the coalition reflects a growing consensus that the bottleneck in computational biology is no longer algorithms but data.

Biohub’s role extends beyond generating measurements to building the connective tissue that lets disparate datasets work in a unified fashion: shared standards, common identifiers, and a single point of access. Equally important, the organization is working to build the scientific community around these resources, convening researchers across institutions and disciplines, connecting complementary expertise and capabilities, and creating opportunities to define and pursue ambitious scientific questions together. The approach builds on a track record from the past decade, during which Biohub has expanded the reach and impact of measurement technologies and open datasets through projects such as Tabula Sapiens, a cross-tissue map of human cell types; OpenCell, an atlas of protein localization and interactions; and Zebrahub, a developmental atlas of the zebrafish. It has also built and maintained community data infrastructure, including CELLxGENE and the CryoET Data Portal, platforms that have become widely used resources for the single-cell and structural biology communities.

For the researchers involved, the payoff of a validated virtual cell could be broad and profound. Nicole Kleinstreuer, NIH Deputy Director for Program Coordination, Planning, and Strategic Initiatives, noted that by combining resources and expertise, the partnership can accelerate the development of universal cell models with sufficient biological complexity to predict how any cell responds to an intervention. The return, she suggested, could be substantially faster timelines for medical breakthroughs compared with attempting to attain the same results through laboratory experiments alone. Alex Rives, Biohub’s Head of Science, put the vision in even starker terms: an accurate predictive model of biology could dramatically accelerate scientific discovery by enabling scientists to perform experiments digitally, unlocking a far greater understanding of disease and opening completely new paths for cures. He called the creation of a virtual cell one of the most important challenges for the next era of science, one that will require coordinated data generation at national and international scale — and he extended an open invitation to the worldwide scientific community to join the project.

The announcement lands at a moment when AI-driven biology is moving from demonstration to application, with structure prediction and molecular design already reshaping drug discovery. What has been missing, experts in the field broadly agree, is the kind of systematic, standardized, openly available measurement data that powered the revolution in language models and, more recently, in protein modeling. By committing $1.8 billion across government, industry, philanthropy, and academia — spanning funding, data, computation, and measurement technology — the Virtual Biology Initiative is betting that the next leap in medicine will come not from a single algorithmic breakthrough but from the patient, coordinated work of measuring life at scale and making the results universally available. Whether the bet pays off will depend on execution across dozens of institutions, but the scale of the commitment signals that the race to simulate biology has officially begun.

Subject of Research: A $1.8 billion international initiative to generate open, AI-ready biological data for predictive models of cells and disease

Article Title: International, cross-sector collaboration commits nearly $2 billion to build foundational data for AI models to predict and treat disease

Article References: International, cross-sector collaboration commits nearly $2 billion to build foundational data for AI models to predict and treat disease. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: Biohub, Virtual Biology Initiative, virtual cell, AI in biology, Department of Energy, NIH, Google DeepMind, Isomorphic Labs, cryo-electron tomography, open data, single-cell biology, predictive models

The research, led by Furlow and colleagues, tackles one of the most consequential prediction problems in critical care. Up to 80 percent of patients who regain spontaneous circulation after cardiac arrest are comatose on admission, and their recovery is frequently uncertain. Because brain injury is the most common cause of death and disability in this population, accurate neuroprognostication is essential, yet reliable predictors remain limited and many apply only to narrow subsets of patients. Current guidelines emphasize a multimodal approach, combining examination findings, EEG patterns, imaging, and biomarkers rather than relying on any single signal. Even so, the process remains as much art as science, and the reasoning behind a withdrawal-of-care decision is often scattered across hundreds of narrative notes.

To build their model, the researchers extracted unstructured text from notes spanning the entire hospitalization of comatose cardiac arrest survivors treated at three hospitals. Natural language processing algorithms processed this text and identified potentially informative keywords, which were then used to train a logistic regression model to predict outcomes on a stratified Cerebral Performance Category scale, the standard framework for grading neurologic recovery after cardiac arrest. The baseline model performed well, achieving an area under the receiver operating characteristic curve of 0.9 and an area under the precision-recall curve of 0.89. Those figures place the note-based model in the range of respectable clinical prediction tools, though the authors caution that performance fell when the model was restricted to notes from only the first 24 hours of admission, with the decline especially pronounced for predicting good outcomes.

That last detail matters enormously, and it is where the accompanying commentary by Sarah Nutman and Christopher Horvat of the University of Pittsburgh sharpens the discussion. Post-cardiac arrest guidelines from the American Heart Association, the European Resuscitation Council and European Society of Intensive Care Medicine, and the Neurocritical Care Society recommend waiting at least 72 hours before attempting to prognosticate, because sedation, targeted temperature management, and the natural evolution of injury can cloud early assessment. A model trained on notes from the first day of admission is therefore being asked to make a judgment that guidelines explicitly say should not yet be made. Nutman and Horvat suggest that the drop in performance on early notes is unsurprising, and that a 72-hour window might have been more instructive for evaluating the model’s true clinical utility.

The commentary also raises a subtler statistical concern: temporal leakage. When a model is trained on notes drawn from the entire hospitalization, the patient’s eventual outcome can become progressively clearer as time passes, so the text may simply echo a conclusion that clinicians have already reached rather than genuinely predicting it. The authors of the original study worried that their models’ weaker performance on good outcomes creates a risk of self-fulfilling prophecies, in which a pessimistic algorithmic prediction influences the decision to withdraw care, thereby making the prediction come true. Nutman and Horvat propose an alternative interpretation: the asymmetry may reflect clinicians incorporating information that never makes it into the written record, leaving the model blind to the very signals that would allow it to recognize patients on a path to recovery.

Perhaps the most provocative contribution of the work is not the AUROC at all, but the window it opens into the hidden architecture of prognostic decision-making. By identifying language patterns associated with withdrawal of life-sustaining treatment, the researchers demonstrated that natural language processing can do more than forecast outcomes; it can interrogate the clinical reasoning, and the possible biases, embedded in routine documentation. Two findings stand out. Keywords related to intimate partner violence were significantly more common in the notes of patients on whom life-sustaining treatment was withdrawn. And although several guidelines recommend against using myoclonus as a prognostic marker, myoclonus appeared significantly more often in the records of patients whose care was withdrawn, raising the possibility that the finding is still quietly influencing bedside decisions despite the guideline warnings.

These observations point toward a use case that extends well beyond prediction. Even without a predictive model, the approach suggests that natural language processing could be deployed to systematically audit differences in clinical outcomes using variables that structured data never captures. In an era when health systems are increasingly attentive to equity, the ability to mine the narrative record for evidence of inconsistent decision-making represents a genuinely novel form of quality control. The same technique that flags a guideline-discordant reliance on myoclonus could, in principle, reveal whether prognostic pessimism is distributed unevenly across patient populations, institutions, or clinical teams.

The study also highlights an underappreciated dimension of prognostication: whose observations count. Neuroprognostication has historically been driven by physician perspectives, yet nurses, therapists, and other health professionals spend far more continuous time at the bedside and often notice changes, in spontaneous movements, responsiveness to family, or sleep-wake cycling, that physicians document less frequently. Incorporating these complementary observations through interdisciplinary evaluation may improve predictions, and the note-mining approach provides a structured mechanism to capture and integrate perspectives from across the clinical team. In that sense, the model is not merely reading the chart; it is aggregating the collective perception of everyone who wrote in it.

Still, significant questions remain before such an algorithm could approach the bedside. Post-arrest guidelines insist on a multimodal approach rather than reliance on any single predictor or algorithm, so the critical unknown is the additive benefit of this tool when used alongside established predictors, including the clinical examination, EEG and neuroimaging findings, and serum biomarkers. The original study compared its model’s performance to other natural language processing models, but not to known neuroprognostic predictors, which limits how much can be said about its incremental value. It also remains unknown whether the algorithm captures anything genuinely new, or whether it simply rediscovers, in narrative form, the same information clinicians already extract from structured testing. A model trained on clinical notes may be learning patient biology, clinician interpretation, family preferences, institutional practice patterns, or an inseparable mixture of all four, and in post-arrest care that distinction is not academic.

The stakes of getting this right could hardly be higher. A falsely pessimistic prediction does not merely misclassify a patient; it can trigger decisions that make the prediction come true, converting an algorithmic error into an irreversible outcome. As Nutman and Horvat conclude, the next step is not to build better note-based models but to determine what these models are actually learning, when their predictions become reliable, and how they should be used alongside established multimodal prognostic tools. Used carefully, natural language processing may help clinicians extract real signals from the clinical record and strengthen one of the most difficult judgments in medicine. Used carelessly, it risks transforming documentation artifacts into clinical authority. The enduring promise of this work lies in making the invisible parts of prognostication visible, and then deciding, with appropriate humility, which of those signals deserve to guide care.

Subject of Research: Natural language processing of clinical notes for neurologic outcome prediction after cardiac arrest

Article Title: Reading Between the Lines After Cardiac Arrest

Article References: Nutman, S. K., & Horvat, C. M. (2026). Reading Between the Lines After Cardiac Arrest. Neurocritical Care. https://doi.org/10.1007/s12028-026-02649-2

Image Credits: AI Generated

DOI: 10.1007/s12028-026-02649-2

Keywords: cardiac arrest, neuroprognostication, natural language processing, machine learning, electronic health records, clinical notes, coma, withdrawal of life-sustaining treatment, EEG, critical care, predictive models, healthcare bias

The paper, written by Marco Viceconti of the Department of Industrial Engineering at the University of Bologna, introduces what the author calls the 7S Framework, a seven-step general procedure for evaluating the credibility of any quantitative estimate, whether it originates from a sensor, a statistical model, or a predictive simulation. The motivation is practical rather than purely philosophical. In fields such as in silico medicine, where computational models increasingly inform clinical decisions and regulatory submissions, a new generation of tools refuses to sit neatly within any one of the traditional categories. In silico-augmented clinical trials, physics-informed machine learning predictors, and machine learning models trained on synthetic datasets all blend measured data, statistical inference, and causal prediction into single estimators, leaving established credibility frameworks unable to cover them cleanly.

To build the framework, Viceconti begins with a conceptual scaffolding often described as the pyramid of knowledge. In this picture, observation lifts raw signals produced by a system of interest into data; annotation with metadata about who, what, where, and when lifts data into information; modelling correlations lifts information into tentative causal beliefs; and subjecting those beliefs to falsification experiments lifts them into actionable knowledge. Quantitative information, in this scheme, is an annotated set of values whose metadata specifies the domain of information, everything sender and receiver must know for the values to be meaningful, but without the causal “why” that would elevate it to knowledge. New information can be created by measurement, which converts signals into data; by inference, which derives new information from existing information; or by prediction, which uses causal knowledge to generate estimates of quantities that were never observed.

From these foundations, the author generalises a vocabulary that statistics normally reserves for inference. The target quantity is the estimand, the value produced is the estimate, and whatever produces it, be it a thermometer, a regression, or a finite element model, is an estimator. Credibility is then defined with a deliberately demanding definition: the minimum accuracy with which an estimator recovers the true value of the estimand across the entire information space, the bounded multidimensional region defined by all the observable quantities on which the quantity of interest depends. Accuracy itself borrows from metrology, where trueness captures systematic error and precision captures random error, combined into a normalised class of accuracy averaged over repeated estimations.

A crucial insight of the paper is that credibility expectations come in three levels, and that these levels are properties of the intended use rather than of the type of estimator. Level 1 credibility demands only that an estimate fall within a predefined uncertainty band around the true value, appropriate when knowing the order of magnitude suffices. Level 2 requires that the average of repeated estimates match the true value in a statistical sense, as when comparing central properties of populations. Level 3 demands local accuracy at every validation point, the standard for subject-specific models intended to predict individual outcomes. A predictive model can therefore be L1, L2, or L3 credible depending on whether it is meant to capture a scale, a population mean, or a person-specific value, and the same hierarchy applies to measurement and inference.

Because brute-force induction, measuring the error at an effectively infinite number of points, is practically impossible and not even theoretically guaranteed for all estimators, the framework follows the strategy shared by metrology, statistics, and VVUQ: decompose the estimation error into its sources and check that each component behaves as theory predicts for a well-behaved estimator. The seven steps formalise this logic. Step S1 defines the context of use and the acceptable error threshold, the maximum error that still leaves the information useful for the decision it must support, and sets this against the limits of validity imposed by the physics of the phenomenon. Step S2 establishes the source of true values, insisting on measurement chains at least an order of magnitude more accurate than the threshold. Step S3 quantifies estimation error through controlled experiments sampled across the solution space. Step S4 identifies the sources of error, which the paper groups into approximation, aleatoric, and epistemic contributions. Step S5 decomposes the overall error among these sources, sometimes requiring special experiments in which all but one error source is excluded. Step S6 critically reviews whether each error component is distributed as expected. Step S7 examines robustness to biases that could emerge in routine use, including applicability, the guarantee that real-world inputs never stray beyond the validity limits explored during assessment. Transparency throughout, particularly about which error sources are considered and how they are separated, is flagged as essential.

The paper demonstrates the framework on seven use cases drawn from the author’s research programme, three of which are summarised in detail. The first concerns strain gauge measurements of bone tissue deformation, used to validate finite element models that predict fracture. The context of use fixes an error threshold derived from the strain difference used to determine fracture, attenuated by two orders of magnitude to account for the chain of inference. True values come from beam-theory calculations on machined aluminium alloy specimens corrected for curvature error; trueness is computed as a root-mean-square error; normality tests confirm the expected distribution of random and systematic errors; and repeated tests on bone specimens establish applicability.

The second case applies the framework to the BBCT-Hip predictor, a biophysical model that estimates mechanical strains in a patient’s bone from a calibrated computed tomography scan. Here the error threshold is set at two percent of the cortical bone failure strain in compression, about 146 microstrain. True values come from strain gauge measurements on carefully preserved cadaveric femurs. The model’s predictions carry numerical, aleatoric, and epistemic errors, and the VVUQ procedure separates them, with the numerical component required to be negligible, the aleatoric component normally distributed with a near-zero mean, and the epistemic component showing a root-mean-square error close to zero. Applicability is probed by exhaustive experiments spanning inter-subject variability and all relevant loading conditions.

The third case is the most forward-looking: assessing a synthetic cohort inferred from a real clinical cohort of elderly patients at risk of hip fracture. The goal is to run in silico trials on virtual populations far larger than any experimentally collected cohort could be, comparing central properties such as means and medians of feature distributions and model predictions. The error thresholds are tied to the measurement and prediction accuracy of each quantity; epistemic error vanishes because the synthetic data are generated by inference, leaving aleatoric error from measurement uncertainty and numerical error from the interpolation functions, which must be shown negligible by sensitivity analysis. Applicability restricts use of the synthetic cohort to the portion of the information space actually sampled by the clinical data.

Viceconi is careful about scope. For estimators that fall squarely into the classical categories, he recommends continuing to use metrology, statistics, or VVUQ, which are more mature and widely accepted within their communities. The 7S Framework is positioned as a supplement for the growing class of hybrid estimators that do not fit anywhere: in silico-augmented trials that inject model predictions into Bayesian device trials, physics-informed neural networks that encode biomechanical law inside learned predictors, synthetic datasets generated to sidestep privacy constraints, and machine learning surrogates trained to replace expensive biophysical simulations. The framework was also applied to cases covering fracture-risk prediction and machine learning surrogates of computational models, and the author reports that it proved effective, sufficiently general, and sensitive to the subtle differences in what credibility means for each information type. Limitations acknowledged include the restriction of the exposition to single scalar quantities, although extension to vectors and time-dependent quantities requires only adding a norm, and the framework’s status as a generalisation rather than a replacement of existing practice. As computational medicine pushes further into regulatory territory, the stakes of getting credibility assessment right rise accordingly, and a shared epistemological vocabulary spanning measurement, inference, and prediction may prove to be exactly what regulators, developers, and clinicians need.

Subject of Research: A general seven-step framework for assessing the credibility of measured, inferred, and predicted quantitative information in computational medicine

Article Title: Assessing the Credibility of Quantitative Information: A General Framework

Article References: Viceconti, M. (2026). Assessing the Credibility of Quantitative Information: A General Framework. Annals of Biomedical Engineering. https://doi.org/10.1007/s10439-026-04367-4

Image Credits: AI Generated

DOI: 10.1007/s10439-026-04367-4

Keywords: credibility assessment, quantitative information, metrology, statistical inference, verification validation and uncertainty quantification, in silico medicine, machine learning predictors, synthetic data, 7S Framework, biomedical engineering, clinical decision-making, predictive models